top of page

Who We Are

Diagno Biotechnology is a startup company built on 20 years of experience in governmental research facilities, academy, and private sector. We decided to create value from the experience and started business in order to  support our sectoral and academic partners.

Our services

Custom antibodies and affinity molecules

We design custom molecules specific for the target you need. After in-silico design, wet lab confirmation is done before delivery.

We provide custom monoclonal antibodies or polyclonal antibodies for your need.

Assay development and consultation

We offer test development and consulting services and create customized test protocols in the sense of our clients' needs. We also provide consultancy services in test development processes and guide our clients through test methods, equipment selection and data analysis.

​Immunoinformatic analyses

We provide Theoretical Kd determination, molecular docking and molecular dynamics analyses for your specific target proteins and molecules.

We conduct small molecule screening.

About Us

Diagno Biotechnology is a startup company built on 20 years of experience in governmental research facilities, academy, and private sector. We decided to create value from the experience and started business in order to  support our sectoral and academic partners.

IMG_6360_edited.jpg
997990b9-79ec-4203-b3ea-2353df36ab33.JPG

Our Vision

Our vision is to be the most trusted and reliable diagnostic supplies company recognized by all potential business and academic partners.

Our Mission

Our mission is to produce, select and supply the highest quality materials for affinity based diagnostic kit development with reasonable budgets.

IMG_6081_edited.jpg

For This Aim

  • We prioritize quality in our product development and production pipelines.

  • We continuously seek for novel partnerships from all over the world to evaluate and test the raw materials from different producers.

  • We help diagnostic kit producing companies to reduce costs without compromising quality in their production pipelines.

bottom of page